1391979-00-2

Basic information

• Product Name: 2-trifluoromethoxy-N-[2-methoxy-5-(4-methyl-6-morpholin-4-ylpyrimidin-5-ylethynyl)-pyridin-3-yl]-benzenesulfonamide
• Synonyms: 2-trifluoromethoxy-N-[2-methoxy-5-(4-methyl-6-morpholin-4-ylpyrimidin-5-ylethynyl)-pyridin-3-yl]-benzenesulfonamide
• CAS NO: 1391979-00-2
• Molecular Weight: 549.53
• Mol File: 1391979-00-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-trifluoromethoxy-N-[2-methoxy-5-(4-methyl-6-morpholin-4-ylpyrimidin-5-ylethynyl)-pyridin-3-yl]-benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-trifluoromethoxy-N-[2-methoxy-5-(4-methyl-6-morpholin-4-ylpyrimidin-5-ylethynyl)-pyridin-3-yl]-benzenesulfonamide(1391979-00-2)
• EPA Substance Registry System: 2-trifluoromethoxy-N-[2-methoxy-5-(4-methyl-6-morpholin-4-ylpyrimidin-5-ylethynyl)-pyridin-3-yl]-benzenesulfonamide(1391979-00-2)

Safety Data

• Hazardous Substances Data: 1391979-00-2(Hazardous Substances Data)

Upstream product

• 1391979-31-9 2-methoxy-5-(4-methyl-6-morpholin-4-ylpyrimidin-5-ylethynyl)pyridin-3-ylamine 
• 103008-51-1 2-(trifluoromethoxy)benzenesulfonyl chloride 
• 152684-30-5 5-bromo-2-methoxy-3-nitropyridine 
• 884495-39-0 5-bromo-2-(methyloxy)-3-pyridinamine 
• 56-04-2 6-methyl-2-thiouracil 
• 3524-87-6 6-methyl-3H-pyrimidin-4-one 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 7752-74-1 5-iodo-6-methyl-3H-pyrimidin-4-one 
• 83410-15-5 4-chloro-5-iodo-6-methyl-pyrimidine 
• 1391979-08-0 4-(5-iodo-6-methyl-pyrimidin-4-yl)morpholine 
• 1391979-12-6 4-(6-methyl-5-trimethylsilanylethynylpyrimidin-4-yl)morpholine 
• 1391979-13-7 4-(5-ethynyl-6-methylpyrimidin-4-yl)morpholine 

Relevant articles and documents

5-Alkynyl-pyridines

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification